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Summary
Background—Although epilepsy affects most patients with tuberous sclerosis complex (TSC),
little is known about the natural history of epilepsy in this genetic disease.
Methods—A retrospective chart review of all patients with TSC seen between January 2002 and
October 2008. Charts were reviewed for a history of infantile spasms (IS), seizure other than IS,
refractory epilepsy, Lennox-Gastaut syndrome (LGS), anticonvulsant medication use, ages of
seizure onset, last seizure, last clinic visit, clinical seizure phenotype(s), cognitive impairment, and
genetic mutation.
Results—Two hundred ninety-one patients were included. Among these patients, 37.8% had a
history of IS; 85.2% had a history of seizure; 54.1% developed multiple seizure types, not
including IS; 63.2% had seizure onset in the first year of life; and 12.1% of adults without a
seizure history developed epilepsy. Of epilepsy patients, 62.5% developed refractory epilepsy and
33.5% achieved epilepsy remission; 37.5% of these patients achieved medication freedom. IS was
a risk factor for refractory epilepsy (p<0.0001) and LGS (p<0.0001). History of seizure, IS, age at
seizure onset, and refractory epilepsy each correlated with poor cognitive outcome (p<0.0001).
Epilepsy remission correlated with better cognitive outcome (p<0.0001). TSC2 was a risk factor
for IS and epilepsy; patients without an identified mutation were more likely to achieve remission.
Conclusion—Most patients with TSC develop epilepsy and most develop multiple seizure types.
Onset typically occurs in the first year of life; however, adults remain at risk. Although refractory
epilepsy is common, many patients achieve seizure control. Many features of seizure history are
predictive of cognitive and epilepsy outcome.
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Tuberous sclerosis complex (TSC) is an autosomal dominant, multiorgan disease with
widely variable expression. TSC is estimated to occur in at least 1 in 6,000 live births,
although true incidence is likely higher due to undetected mild cases (Webb & Osborne,
1995; Crino et al., 2006). Approximately 85% of patients with TSC are found to have a
mutation in one of two genes, TSC1, encoding hamartin, or TSC2, encoding tuberin (Dabora
et al., 2001; Sancak et al., 2005). Protein products of these genes have been shown to form a
heterodimer (TSC1–TSC2 complex) that inhibits the mammalian target of rapamycin
(mTOR) signaling cascade (Astrinidis & Henske, 2005; Kwiatkowski & Manning, 2005).
Inadequate suppression of the mTOR pathway results in dysgenic lesions in multiple organ
systems, including cortical tubers, radial glial bands, subependymal nodules, and
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subependymal giant cell tumor formation in the fetal and developing brain (Crino, 2004;
Sarbassov et al., 2005; Sabatini, 2006).
Epilepsy is the most common neurologic symptom in patients with TSC, and a significant
source of morbidity and mortality (Shepherd et al., 1991; Thiele, 2004; Holmes et al., 2007).
Although epilepsy is known to affect the majority of patients with TSC, reports of the
prevalence of epilepsy and infantile spasms in varied, smaller TSC populations have been
inconsistent (Webb et al., 1991, 1996; Roach et al., 1998; Jozwiak et al., 2000; Cross, 2005;
Crino et al., 2006; Devlin et al., 2006). Furthermore, there have been few studies evaluating
the natural history of epilepsy in TSC (Webb et al., 1996).
In order to better characterize and understand epilepsy in TSC, we sought to describe the
prevalence of epilepsy and infantile spasms in our large pediatric and adult TSC clinic. We
further set out to describe in detail the natural history of epilepsy in TSC, including age of
onset, frequency of multiple seizure types, evolution to refractory epilepsy, prevalence of
Lennox-Gastaut syndrome, and likelihood of achieving seizure-freedom and medication-
freedom. We further evaluated the relationships among epilepsy history, cognitive outcome,
and genetic mutation in our patient population.
Methods
We performed a retrospective chart review of all patients seen at Herscot Center for
tuberous sclerosis complex at Massachusetts General Hospital between January 2002 and
October 2008. Patients were included if they met clinical criteria for definite TSC (Roach et
al., 1998). Two hundred ninety-one patients were included.
Patient charts were reviewed for genetic mutation, history of infantile spasms, history of
seizure other than infantile spasms, age at seizure onset (in 1-month intervals), age at last
seizure (in 1-month intervals), age at last clinic appointment (in 1-month intervals), history
of epilepsy, clinical seizure phenotype(s), refractory epilepsy, history of Lennox-Gastaut
syndrome (LGS), epilepsy surgery history, anticonvulsant medication history including
discontinuation, and cognitive impairment. Seizure types were classified by an experienced
epileptologist strictly according to clinical semiology provided by direct observation in
clinic or by description by a witness.
For the purpose of this article, epilepsy was defined as at least two clinical seizures not
including infantile spasms, which were considered separately in our analyses. Refractory
epilepsy was defined as uncontrolled seizures after at least three first-line anticonvulsant
medication trials. Patients were considered seizure-free if they were without clinical seizures
for at least 1 year, using the last clinic visit documenting seizure status as the endpoint of
follow-up. Definite LGS was defined as characteristic generalized slow spike and wave
pattern on electroencephalography (EEG), at least three generalized seizure phenotypes
(atypical absence, myoclonic, generalized tonic–clonic, and/or atonic), and cognitive
impairment. Probable LGS was defined as two of the above criteria, with insufficient data
available for review for the third category. Genetic testing of the TSC1 and TSC2 genes,
including detection of large DNA deletions and rearrangements of the TSC2 gene, was
performed at Athena Diagnostics (Worcester, MA, U.S.A.) or the MGH Neurogenetic
Diagnostic Laboratory (Boston, MA, U.S.A.). Patients for whom genetic testing was
inconclusive were classified as no mutation identified (NMI).
Formal neuropsychological evaluations were available for review in 126 patients. When an
intelligence quotient (IQ) was not obtained, a developmental quotient (DQ) was calculated
by dividing the mental age of the child by his or her chronological age and multiplying by
100. Those with an IQ or DQ<70 were considered cognitively impaired. If formal
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neuropsychological testing was not performed, intellectual status was determined by an
experienced pediatric neurologist based on developmental examination, school performance,
activities of daily living, and language abilities. If cognitive function was unknown, patients
were excluded from analysis.
Statistical analyses were performed using logistic regression, chi-square analyses, and
Fisher’s exact test. All reported p-values used two-tailed tests of significance with α set at
0.05.
The institutional review board of the Massachusetts General Hospital approved this study.
Results
Descriptive statistics of epilepsy
Two hundred ninety-one patients with definite clinical TSC were included. Two hundred
forty-eight patients had a history of at least one seizure (85.2%). Of these patients, 246
developed epilepsy (99.2%). Two patients (0.8%) had only a single seizure (3.75 years and
21.2 years of follow-up). One hundred fifty-five of 248 patients (62.5%) developed
refractory epilepsy.
One hundred ten of 291 patients (37.8%) had a history of infantile spasms. Only four
patients with a history of infantile spasms (3.6%) did not develop another seizure type, and
two of these patients are currently only 2 years of age, thus limiting follow-up. Of patients
with a history of infantile spasms, 83 of 110 (75.4%) developed refractory epilepsy
compared with 72 of 181 patients (39.8%) without a history of infantile spasms (p<0.0001).
Of the 248 patients with a history of seizure, seizure types were documented for 237
(95.6%) (Fig. 1). Excluding infantile spasms, 126 of 237 patients (53.2%) had more than one
seizure type. At least one seizure phenotype with a clear focal onset clinically (simple partial
or complex partial seizures with or without secondary generalization) was documented in
221 of 237 patients (93.2%).
Age at seizure onset was known for 231 patients (Fig. 2). The most common age at seizure
onset was 3 months (average 29.0 months, median 7 months, range 1 day to 45.4 years).
Seizure onset occurred within the first 4 weeks of life in 15 patients (6.5%), before 6 months
of age in 106 patients (45.8%), by the end of the first year of life in 146 patients (63.2%),
and before 3 years of age in 188 patients (82.1%). First seizure occurred after age 13 years
in five patients (2.2%). Among 33 TSC adults without a history of seizure, four (12.1%)
subsequently developed epilepsy.
Of patients with epilepsy, clinical follow up was available for 242. Eighty-one (33.5%) of
242 patients were seizure-free for at least 12 months at last clinic visit. These patients had
clinical follow-up of an average of 11.8 years after last seizure [standard deviation (SD) 11.4
years, median 6.9 years, mode 4.0 years, range 12 months to 51.6 years]. Of 81 seizure-free
patients, 33 patients underwent attempted medication wean and 30 (37.5%) of 81 remained
seizure-free off medication. Average age of seizure-freedom was 13 years 0 months (SD
16.3 months, mode 8 years, range 8 months to 56.5 years).
Of 155 patients with refractory epilepsy, 29 (18.7%) subsequently achieved epilepsy
remission. Ten (25.6%) of 39 patients with refractory epilepsy who underwent epilepsy
surgery achieved seizure freedom and 19 (16.4%) of 116 patients who did not undergo
epilepsy surgery became seizure-free. This comparison was not statistically significant
(p=0.24). One patient with medication refractory epilepsy achieved seizure freedom 3
months after placement of a vagus nerve stimulator (VNS) and has subsequently remained
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seizure-free with combination anticonvulsant treatment and VNS for 4 years and 3 months.
No patients included in this study achieved seizure freedom while on dietary therapy for
epilepsy.
Of 248 patients with a history of seizure, 15 patients (6.0%) developed LGS. Fifty-three
further patients (21.4%) had probable LGS. Of patients with a history of infantile spasms, 43
of 110 (39.1%) developed definite or probable LGS, compared with 25 (13.8%) of 181
patients without a history of infantile spasms (p<0.0001).
Relationship of epilepsy to cognitive outcome
Results are shown in Table 1. Of 256 patients whose cognitive function was documented,
120 (46.9%) were cognitively normal. Formal neuropsychological testing results with
estimated IQ or DQ was available for 126 patients (mean 68.5, SD 32.37, range 7–137).
Of patients with a history of seizure, 131 of 215 (60.9%) were cognitively impaired
compared with 5 of 41 patients (12.2%) without a history of seizure (p<0.0001). Of patients
with a history of infantile spasms, 73 of 98 (74.4%) were cognitively impaired, compared
with 62 of 158 patients (39.2%) without a history of infantile spasms (p<0.0001).
Cognitive outcome and IQ were significantly related to age of seizure onset (logistic
regression, p=0.004 and p=0.000; Table 2). When patients with a history of infantile spasms
were removed from analysis, the relationship between age at seizure onset and IQ remained
significant (logistic regression, p=0.006). There was no difference in cognitive outcome
between patients ≤6 months of age at seizure onset compared with those between 7 and 12
months of age (p=0.16; Fig. 2). Notably, 6 (33.3%) of 18 patients with seizure onset at ≤1
month of age had normal cognitive outcome. Three of these cognitively normal patients also
had a history of infantile spasms. Patients with seizure onset before 3 years of age were
more likely to be cognitively impaired than patients with seizure onset after 3 years of age (p
< 0.0001). There was no relationship between cognitive outcome and age of seizure onset
for patients <3 years of age (logistic regression, p = 0.165).
Of 142 patients with a history of refractory epilepsy 104 (73.2%) were cognitively impaired
compared with 28 of 74 patients (37.8%) without a history of refractory epilepsy (p <
0.0001). Of 74 patients who were seizure-free, 42 (56.7%) were cognitively normal
compared with 43 of 142 (30.2%) who were not seizure-free (p < 0.0001).
Relationship of epilepsy to genetic mutation
Results are shown in Table 3. Of 291 patients with TSC, 231 underwent genetic testing: 123
(53.2%) were found to have a TSC2 mutation, 60 (26.0%) a TSC1 mutation, and 48 NMI
(20.8%).
Of 123 patients with a TSC2 mutation, 112 (91.0%) had a history of seizure compared with
51 of 60 patients (85%) with a TSC1 mutation and 34 of 48 patients (70.8%) with NMI
(p=0.004). Subgroup analysis revealed that patients with TSC2 were more likely to have a
history of seizure compared with patients with NMI (p=0.001), but not TSC1 (p = 0.22).
Of patients with a history of seizure, 76 of 112 patients (67.9%) with a TSC2 mutation
developed refractory epilepsy compared with 27 of 51 patients (52.9%) with a TSC1
mutation and 20 of 34 patients (58.8%) with NMI (p = 0.169).
Of 123 patients with a TSC2 mutation, 69 (56.1%) had a history of infantile spasms
compared with 6 of 60 patients (10%) with a TSC1 mutation and 12 of 48 patients (25.0%)
with NMI (p < 0.0005). Subgroup analysis revealed that patients with TSC2 were more
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likely to have a history of IS compared with patients with TSC1 (p < 0.0005) or NMI (p <
0.0005). Patients with NMI were more likely to have a history of IS compared with patients
with TSCI (p = 0.021).
Among patients with clinical follow-up available, 18 of 33 patients (54.5%) with NMI
became seizure-free compared with 34 of 122 patients (27.9%) with TSC2 mutation and 17
of 50 patients (34.0%) with TSC1 mutation (p = 0.016). On subgroup analysis, patients with
NMI were more likely to become seizure-free than patients with TSC2 (p = 0.004) but not
patients with TSC1 patients (p = 0.064), although there was a trend.
Discussion
Previous data obtained from small cohorts of patients seen in neurology clinics estimate the
prevalence of epilepsy in TSC to be 93–96% (Jozwiak et al., 2000; Devlin et al., 2006). A
small, unbiased genetic linkage study estimated a prevalence of 62% (Webb et al., 1991). In
a large cohort of 291 patients with TSC seen in a specialty clinic, we found that 85.2% have
a history of seizure and 84.5% met criteria for clinical epilepsy. The high prevalence of
infantile spasms in TSC is a consistent observation, although estimates of previous studies in
varied populations vary from 27–96% (Pampiglione & Moynahan, 1976; Webb et al., 1996;
Jozwiak et al., 2000; Curatolo et al., 2001; O’Callaghan et al., 2004). In this large cohort, we
found a history of infantile spasms in 37.8%. It is routine in our clinic to screen and treat
identified family members with subclinical disease, and our estimates include both
symptomatic probands as well as subclinical family members. However, these results are
still likely overestimated due to referral bias. Unavailable remote clinical histories in newly
referred adult patients may contribute an underestimation of infantile spasms.
In patients with TSC, the likelihood of developing epilepsy after presenting with a single
seizure is nearly 100%, and, therefore, strong consideration should be given to treat with
anticonvulsant medication after first seizure. Even among known epilepsy patients, frequent
surveillance for new paroxysmal events is necessary, as nearly all patients with infantile
spasms develop another seizure phenotype and more than half of epilepsy patients develop
multiple seizure types. Classic seizures with focal onset are seen in most patients with TSC;
however, many patients also had seizure phenotypes that appeared clinically generalized at
onset. The number of patients with true primary generalized seizures was likely
overestimated, as clinical data was used for seizure characterization rather than ictal EEG
recordings. Given the focal neuropathologies found in TSC, it is likely that most seizures are
partial in onset, with or without rapid secondary generalization.
Similar to previous reports, we found that nearly two-thirds of patients had seizure onset
within the first year of life (Webb et al., 1996; Gomez, 1999; Jozwiak et al., 2000).
Furthermore, nearly 80% of patients had seizure-onset within the first 3 years of life.
Despite the strong propensity for patients with TSC to develop epilepsy in childhood, we
found that >12% of adult patients without a previous history of seizure subsequently
developed epilepsy, indicating that patients with TSC remain at significantly increased risk
of epilepsy throughout their lifetime.
The cognitive impact of each infantile spasms and refractory epilepsy has been shown
previously and is supported here (Webb et al., 1996; Goh et al., 2005; Winterkorn et al.,
2007; Jansen et al., 2008a). In our cohort, nearly two-thirds of epilepsy patients with TSC
develop refractory epilepsy compared with 23.2% reported in the general epilepsy
population (Berg et al., 2006). We have further shown that age of seizure-onset correlates
with cognitive outcome independent of infantile spasms. Previous work in a smaller
population found that seizure onset in the first year was associated with poor cognitive
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outcome (Jansen et al., 2008b). In our cohort, children with seizure-onset before 3 years of
age were at increased risk of cognitive impairment; however, those with seizure onset at <1
year were not at further increased risk.
Although epilepsy can be difficult to manage in TSC, one-third of patients achieved epilepsy
remission, including nearly 20% of patients with a history of refractory epilepsy. The
majority of patients in whom epilepsy remission was achieved were cognitively normal.
Although few patients in this study achieved seizure freedom on dietary therapy or with
VNS, these nonpharmacologic options have been found to significantly reduce the
frequency of seizures in this patient population and should be considered (Kossoff et al.,
2005; Jansen et al., 2007; Major & Thiele, 2008). Subsequent to the termination of this
study, we do have one patient with medication refractory epilepsy who has been seizure-free
for >10 months on low-glycemic index dietary treatment.
A prior study evaluating 15 children with TSC found that more than one-fourth experienced
seizure relapse after anticonvulsant discontinuation (Sparagana et al., 2003). In our
population, nearly one-third of seizure-free patients were also medication-free, and only 3 of
33 (9.1%) of patients experienced recurrent seizure after attempted medication taper. This
discrepancy may be due to differences in the populations studied, as both adults and children
were included in our study, as well as differences in clinical practice, given that we routinely
require at least 1 year without clinical seizures and improved or resolved EEG abnormalities
prior to attempted medication wean. Carefully selected, well-controlled patients should be
considered for medication taper even in this high-risk population.
Previous work evaluating genotype–phenotype relationships in patients with TSC1 and
TSC2 have similarly found that patients with TSC2 mutations experience higher frequency
of seizures than those with TSC1 mutations (Dabora et al., 2001; Jansen et al., 2008a). We
have further shown that the risk of infantile spasms is greatest among patients with TSC2
mutations followed by those with NMI. Furthermore, NMI patients with epilepsy were most
likely to achieve seizure freedom. It is likely that at least some NMI patients are TSC1 or
TSC2 mosaics, which could explain the mixed clinical features seen in this group. It has
been postulated that some retention of function of the tuberin GTPase activating protein
(GAP) domain could account for the decreased clinical severity seen in TSC1 patients.
However, previous work has not found a relationship between infantile spasms and deletions
predicted to impact the GAP domain among TSC2 patients (Jansen et al., 2008a). Further
work in animal and cell models measuring the functional activity of the hamartin–tuberin
complex as it relates to genotype is needed.
In summary, in a large population of patients with TSC attending a tertiary care center,
epilepsy remains a major source of morbidity, particularly for young children. Careful
surveillance and prompt and aggressive treatment of epilepsy remains critical to minimize,
and potentially prevent, the adverse impacts of uncontrolled seizures in this at-risk
population.
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CPS, complex partial seizures (includes CPS with secondary generalization); IS, infantile
spasms; GTC, generalized tonic–clonic seizures; SPS, simple partial seizures (includes SPS
with secondary generalization); ESES, electrographic status epilepticus of sleep.
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Distribution of age at seizure onset among 231 patients with tuberous sclerosis complex.
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Table 1
Relationship of epilepsy history to cognitive outcome
Cognitively impaired (%) Cognitively normal (%)
History of seizurea
 Yes 131 (60.9) 84 (39.1)
 No 5 (12.2) 36 (87.8)
Infantile spasmsa
 Yes 73 (74.4) 25 (25.6)
 No 62 (39.2) 96 (60.8)
Age of seizure onseta
 <3 years 114 (32.1) 54 (67.9)
 ≥3 years 7 (80.6) 30 (19.4)
Refractory epilepsya
 Yes 104 (73.2) 38 (26.8)
 No 28 (37.8) 46 (62.2)
Epilepsy remissiona
 Yes 32 (43.3) 42 (56.7)
 No 99 (69.8) 43 (30.2)
a
Denotes statistically significant comparison.
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Table 2
Age at seizure onset of 231 patients with TSC and cognitive outcome
Age (years) Cognitively normal (%)a Cognitively impaired (%)a Cognitive status unknown Total (N = 231) (%)
<1 39 (29.5) 93 (70.5) 14 146 (63.7)
1 12 (42.9) 16 (57.1) 4 32 (14.0)
2 3 (37.5) 5 (62.5)b 2 10 (4.4)
3 1 (100) 0 (0) 0 1 (0.4)
4 6 (100) 0 (0) 1 7 (3.1)
5 6 (75) 2 (25) 1 9 (3.9)
6 4 (100) 0 (0) 1 5 (2.2)
7 3 (75) 1 (25) 0 4 (1.7)
8 2 (66.7) 1 (33.3) 1 4 (1.7)
9 1 (100) 0 (0) 0 1 (0.4)
10 1 (100) 0 (0) 0 1 (0.4)
11 1 (100) 0 (0) 1 2 (0.9)
12 2 (50) 2 (50) 0 4 (1.7)
13 0 (0) 0 (0) 0 0 (0)
14 0 (0) 0 (0) 0 0 (0)
15 0 (0) 0 (0) 1 1 (0.4)
16 0 (0) 0 (0) 0 0 (0)
17 0 (0) 0 (0) 0 0 (0)
>18 3 (75) 1 (25) 0 4 (1.7)
a
Percentage of patients (among those with known cognitive status).
b
Patients with seizure onset prior to age 3 were significantly more likely to have cognitive impairment compared to patients with seizure onset after
age 3 (p < 0.0001).
TSC, tuberous sclerosis complex.
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Table 3
Relationship of epilepsy prognosis to genetic mutation
TSC1 (%) TSC2 (%) NMI (%)
History of seizurea 51/60 (85) 112/123 (91.0) 34/48 (70.8)
Refractory epilepsy 27/51 (52.9) 76/112 (67.9) 20/34 (58.8)
Epilepsy remissiona 17/50 (34.0) 34/122 (27.9) 18/31 (54.5)
a
Denotes statistically significant comparison.
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